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Abstract
Background: In many clinical conditions that involve free flaps and tissue transplantations the possibility of minimizing
ischemia-reperfusion injury can be a determinant factor for the success of the surgery itself. We hypothesize that
preconditioning with sevoflurane is a protective factor against ischemia-reperfusion injury.
Methods: In this randomized controlled trial, patients ASA I-II undergoing breast reconstruction with deep inferior
epigastric perforator flaps were allocated into two groups and analyzed: group BAL included patients who received
balanced anesthesia with sevoflurane for 30 min before removal of the flap and throughout the surgery. The TCI group
included patients who received a total intravenous anesthesia with propofol and remifentanil. We evaluated regional
tissue oximetry at the end of the surgery and at 4, 12 and 20 h after surgery. Other assessed parameters were: blood
lactate clearance, alanine aminotransferase, aspartate aminotransferase, lactic dehydrogenase, creatine phosphokinase.
Results: In total 54 patients, twenty-seven per group, were analyzed. There was a significant increase of the average
value of regional tissue oximetry measured 4 h after surgery in the BAL group compared to the TCI group: BAL: 84.05 %
(8.96 SD); TCI : 76.17 % (12.92 SD) (P = 0.03), but not at the other time frames. The creatine phosphokinase value was
significantly lower in the BAL group at the end of surgery, but not at the other time-frames. There were no significant
differences in blood levels of other markers.
Conclusions: From our results, the positive preconditioning impact of sevoflurane on ischemia-reperfusion injury
in patients undergoing free flap surgery is expressed in the early postoperative hours, but it does not persist in
the long-term.
Trial registration: ClinicalTrial.gov identifier: NCT01905501. Registered July 18, 2013
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Background
The ischemia-reperfusion (IR) injury is a pathological
condition characterized by an initial restriction of blood
flow to an organ, followed by restoration of perfusion
and oxygenation; this generates a set of complex mecha-
nisms that culminate with vascular, biochemical and cel-
lular changes. The ischemic period produces endothelial
stress, cellular alteration and reduced levels of high-
energy metabolites such as adenosine triphosphate
(ATP), along with the production of free radicals and
neutrophilic activation. Reperfusion provides a signifi-
cant amount of oxygen that is converted into reactive
species of oxygen, which elicit changes in mitochondrial
permeability, alterations of the membranes and the
emission of preapoptotic molecules [1]. Free radical acti-
vation of neutrophils amplifies endothelial damage; the
modification of intracellular ions’ concentration, with
ATP depletion, contributes to the processes of cell ne-
crosis [2].
IR injury is inevitable in many clinical conditions that
involve tissue transplantation and free flaps. In recon-
structive plastic surgery with free flaps, the control of IR
injury can have a significant impact, playing a decisive
role in the outcome of the surgery itself. For these rea-
sons, research on methods that protect tissues from
damage associated with molecular IR is particularly im-
portant. In recent years, the role of sevoflurane adminis-
tration before the occurrence of the ischemic process
(preconditioning) has been widely investigated as a pro-
tective factor against IR injury in different settings [3].
Many studies have been conducted on sevoflurane
myocardial preconditioning in cardiac patients undergo-
ing cardiac [4] and non-cardiac surgery [3–5], and a re-
cent meta-analysis showed that the use of halogenated
anesthetics in cardiac surgery reduces the rate of mor-
bidity and mortality [6].
In general, the effect of cardiac sevoflurane precondi-
tioning has been related to the endothelial protection [7]
and to the beneficial effects on inflammatory response
[8, 9]. Therefore, it can reasonably be assumed that this
method has a protective effect on other ischemic tissues
as well [10, 11].
Our study aims to evaluate the possible protective ef-
fect of a balanced anesthetic technique (BAL), compared
to a total intravenous anesthetic technique using target-
controlled infusion (TCI), on ischemic reperfusion con-
ditions, inevitably generated in patients undergoing
reconstructive surgery with a microvascular flap. For this
purpose, we assessed the metabolic status of the flaps by
using continuous regional tissue oximetry (rSO2) and by
monitoring the levels of biochemical markers in the
postoperative period.
At the current state of our knowledge, there are no
other studies evaluating the effect of sevoflurane precon-
ditioning on microvascular free flaps in plastic surgery.
Our hypothesis is that in the group of patients receiv-
ing sevoflurane preconditioning there is a statistically
significant increase in rSO2 measured by employing a
near-infrared spectroscopy monitor.
Methods
A multi-center prospective, randomized study was con-
ducted in the period between July 2013 and November
2014, at the Regina Elena National Cancer Institute,
Rome (Italy) and at the Sacro Cuore Catholic University,
Rome (Italy). The study was approved by the Central
Ethics Committee of National Cancer Institute Regina
Elena and Sacro Cuore Catholic University, Rome, Italy
(Chairperson Dr Anna D’Ambrosio), with Protocol n.
CE/67/13, and retrospectively registered with Clinical-
Trial.gov identifier: NCT01905501. Clinical investigation
was conducted according to the principles expressed in
the Declaration of Helsinki.
After written informed consent, ASA I-II patients can-
didate for free deep inferior epigastric perforator (DIEP)
flaps for breast reconstruction were enrolled. Patients
under the age of 18, those with known unusual reaction
to anesthetic drugs, the ones with a history of vascular
disease or of bleeding diathesis and others with nicotine
addiction were all excluded from the study.
Patients were randomly divided into two treatment
groups by an operator who is not directly involved in
the study and according to a specific dedicated software,
developed in-house, by GW Basic (Microsoft Corpor-
ation, USA) programmer, which generated an assign-
ment code verified immediately before inducing
anesthesia. Surgeons were blinded to the intervention
and a blinded observer recorded the outcome.
In both groups, patients were premedicated with mid-
azolam 0.01 mg/kg and general anaesthesia was induced
with fentanyl 3–5 mcg/kg, propofol 2 mg/kg, and cisa-
tracurium 0.07 mg/kg. After tracheal intubation, in the
first group (BAL) anesthesia was maintained with a mix-
ture of sevoflurane/oxygen/air, adjusted to provide an
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end-tidal sevoflurane of 1.5–2 vol.%, and remifentanil,
adapted according to a TCI range of 2–4 ng/ml. This
anesthesia was always started at least 30 min before flap
removal. In the second group (TCI) anesthesia was
maintained with propofol 3–4 μg/ml and remifentanil
2–4 ng/ml according to TCI protocol. In both groups,
patients were ventilated with positive pressure ventila-
tion in volumetric mode. Ventilator parameters were ad-
justed to perpetuate an end-tidal CO2 (etCO2) between
30 and 37 mmHg and a tidal volume of 6–8 ml/kg.
The same fluid protocol was used by the anesthesiologi-
cal equipe in both groups: the fluid therapy regime was
mainly restrictive, according to basal infusion of crystalloid
variable from 2 to 4 ml/kg/h. Arterial blood pressure
(ABP) was regulated by titraing remifentanil and fluid ad-
ministration in order to maintain a target at values be-
tween 65 and 95 mmHg. It was possible to administer
boluses of colloids (HES 130/0.4) of 250 ml in 15 min if
mean arterial pressure was ≤ 70 % of preinduction.
The standard monitoring for all patients consisted in
continuous electrocardiogram, heart rate (HR), ABP meas-
urement, pulse oximetry (SpO2), inspired and expired gas
and capnometry. In all patients, regional tissue oximetry
(rSO2) was measured employing a near-infrared spectros-
copy (NIRS) monitor with In-Vivo Optical Spectroscopy
System (INVOS™, Covidien, Boulder, CO). The INVOS™
sensors were placed directly on the transplanted flap at
the end of surgery. The spectrophotometric values were
determined at the end of the surgery (T0), and at 4, 12
and 20 h after surgery (respectively T1, T2 and T3). Post-
operatively, ABP, HR, SatO2 were recorded at the same
time point. Other parameters evaluated were: blood lactate
clearance, alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), lactic dehydrogenase (LDH), creatine
phosphokinase (CPK). All blood markers were quantified
preoperatively, at the end of the surgery, and at 4 and 20 h
after surgery.
In all patients the main hemodynamic parameters
(ABP, HR, SpO2, FiO2, etCO2) were recorded every
hour during surgery.
Furthermore, duration of surgery, incidence of patients
who were transfused, incidence of patients with surgical
site infection, as stated by the Centers for Disease Con-
trol (CDC), and those in need of surgical re-exploration
within 7 postoperative days were also assessed.
Statistical analysis
The study was designed as a two-arm parallel, prospect-
ive, randomized trial. The primary endpoint was consid-
ered the rSO2. Assuming an alpha error of 5 %, power
of 80 % and a dropout rate of 10 % and using a previous
data analysis of a group of patients that preceded this
study and which was not included in it, we considered
rSO2 = 80 % ± 10 (sd) as a reference value for the control
group and we theorized a 10 % improvement. We esti-
mated a sample size of 54 patients (27 per group) to de-
tect a minimum 10 % (effect size d = 0.8) estimated
clinically significant difference between the groups.
Two-way repeated-measures analysis of variance
(ANOVA) was used to test the differences in continuous
variables between groups and over time. This analysis
allowed us to correctly evaluate repeated observations
on patients and to test the effect of this experimental
treatment and the variables’ trend throughout the obser-
vation time. Differences between continuous variables at
specified time intervals were subsequently evaluated
with Student’s t-test. Dichotomous variables were ana-
lyzed using Fisher’s exact test. Variables are presented as
means.
The threshold for statistical significance was set at
P < 0.05. Computerized statistical analysis was per-
formed with the Statistical Package for the Social
Sciences software, version 20.0 (IBM SPSS Statistics,
Chicago, IL, USA).
Results
The flowchart of the patients who participated in the
study is shown in Fig. 1. In total, 54 patients were ana-
lyzed after randomization: 27 patients were assigned to
the BAL group and 27 to the TCI group. The demo-
graphic and clinical data is presented in Table 1. There
were no significant differences between groups in terms
of age, body mass index (BMI), comorbidity, type and
duration of surgery, ASA classification and cancer type.
The intraoperative hemodynamic data recorded is
shown in Fig. 2. In the BAL group, the heart rate re-
mains significantly higher for the entire duration of sur-
gery. There are no significant differences between the
groups regarding other intraoperative values.
The mean regional tissue oximetry value in the four
time frames for the BAL group and TCI group re-
spectively was as follows: T0: 81.8 % (8.4 SD) and
76.8 % (11.4 SD) (P = 0.13); T1: 84 % (8.9 SD) and
76.1 % (12.92 SD) (P = 0.03); T2: 84.8 % (10 SD) and
80.3 % (14.4 SD) (P = 0.27); T3: 85.4 % (9.9 SD) and
80.6 % (18.6 SD) (P = 0.32). Values of blood lactate
clearance, alanine aminotransferase, aspartate amino-
transferase and lactic dehydrogenase are not statisti-
cally different in the two groups for the duration of
the monitoring. However the creatine phosphokinase
value was significantly lower in the BAL group at the
end of the surgery, but not at the other time frames:
preoperatively: 68.7 (54 SD) in the BAL group and
56.4 (31.1 SD) in the TCI group (P = 0.31); at the end
of the surgery: 133.6 (74.1 SD) in the BAL group and
184.1 (100.2 SD) in the TCI group (P = 0.04); at 4 h
after surgery: 293.8 (238.6 SD) in the BAL group and
294.2 (160.7 SD) in the TCI group (P = 0.99); at 20 h
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after surgery: 495.2 (530.2 SD) in the BAL group and
427.6 (305.2 SD) in the TCI group (P = 0.58) (Table 2).
There were no significant differences between groups
in the recorded postoperative hemodynamic parameters
(Fig. 3), nor in transfusion incidence, surgical site infec-
tion incidence, duration of surgery and surgical re-
exploration incidence (Table 1).
Discussion
In our study, we tried to assess the damage from ische-
mia reperfusion in two groups of patients undergoing
DIEP flap for breast reconstruction.
As a marker of ischemia reperfusion, regional tissue O2
saturation in the 24 h following surgery was evaluated,
along with blood levels of lactate, transaminases, lactic de-
hydrogenase and creatine phosphokinase. Conversely, the
failure of the microsurgical flap was not considered a valid
outcome to assess the damage from ischemia reperfusion
since it is influenced by numerous technical variables
(proper surgical technique, involvement of more than one
microvascular surgeon, intraoperative fluid administra-
tion). However, the incidence of surgical site infection and
surgical re-exploration were recorded.
The regional tissue oximetry is based on blood chro-
mophores’ different characteristics of absorption of the
near infrared light, in particular hemoglobin and deoxy-
hemoglobin’s absorption. This system, reflecting the bal-
ance between oxygen supply and demand, is a validated
non-invasive and reproducible [12] method for con-
tinuous surveillance of oxygenation and perfusion of
the analyzed tissue. In plastic surgery this technology is
already widely used to monitor free tissue transfers [13,
14], not only for breast free flaps, but also in head, neck
[15, 16] and lower extremity flaps [17].
Fig. 1 Patient disposition
Table 1 Demographics, perioperative and postoperative profile
(Results, pag 8, line 156 and page 9, line 177)
BAL Group TCI Group P value
(n =27) (n =27)
Age (years) 50 (7.5) 52.7 (7.8)
BMI (kg m−2) 22.2 (2.7) 23.1 (2.9)
ASA score (I/II) 22 (81.4)/5 (18.6) 25 (92.6)/2 (7.4)
Comorbidities:
dyslipidemia 2 (7.4) 0
hypertension 1 (3.7) 1 (3.7)
Patients transfused 0 0
CDC surgical site infection 1 (3.7) 3 (11.1) 0.64
Surgical re-exploration 6 (22.2) 4 (14.8) 0.49
Lenght of surgery (min) 398 (39.1) 417 (50) 0.12
Data is expressed as mean (SD) or number of patients (%)
BMI body mass index, ASA American Society of Anesthesiologists, SD standard
deviation, CDC Centers for Disease Control
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Our results show that there is a significant increase of
the average value of rSO2 measured according to
INVOS at 4 h after surgery in the BAL group. It was also
increased in other time frames and compared to average
values, but not in a statistically significant manner. The
CPK at the end of the surgery is also significantly lower
in the sevoflurane group, but the difference in the two
groups tends to disappear in later times.
From the results obtained, we can assert that there is an
improvement of flap oxygenation with sevoflurane pre-
conditioning, but this effect seems to be limited in time,
and as hours pass the level of tissue oxygenation returns
comparable to the one of not preconditioned tissue.
Congruent with our results, Balzan and colleagues [18]
in their study on animals subjected to hepatic precondi-
tioning with sevoflurane, found lower levels of C-
reactive protein after ischemia, which increased in fol-
lowing time frames, and they concluded that the protect-
ive effect is mainly circumscribed to the initial phase of
injury whereas it lessens as time elapses.
In a recent review, Swyers [19] described two possible
phases of sevoflurane protection in ischemia reperfusion
injury, with a mechanism similar to the protective effect
of ischemic preconditioning. Swyers attributed the pro-
tective effect of volatile anesthetics to their ability to
interact with the multi-signaling pathway of mitochon-
drial K-ATP channels. The action mechanism proposed
was to hinder the entry of calcium ions in the mitochon-
dria, allowing the functionality of the mitochondrial
membrane to remain unaltered, mimicking the early
phase of ischemic preconditioning. Most of studies in lit-
erature have focused on the early phase of protection,
but the duration of the beneficial effects of precondition-
ing with volatile anesthetics remains uncertain. The early
phase protection appears immediately after ischemic
stimuli, but disappears within 2–4 h. The late phase pro-
tection emerges around 12 to 24 h after the initial ische-
mic preconditioning and lasts for 2 or 3 days [20, 21].
Some studies [22, 23] have identified adenosine and ni-
tric oxide as the vasoactive mediators that begin a com-
plex signal transduction cascade involving the activation
of transcription factors which results in the synthesis of
effector proteins. These effector proteins may confer
cytoprotection in the second phase of prolonged ischemic
Fig. 2 Intraoperative data. All data presented as mean (standard deviation). * Significant. MAP: mean arterial pressure. EtCO2: end tidal carbon
dioxide. FiO2: fraction of inspired oxygen. SpO2: saturation of peripheral oxygen. HR: heart rate. Bpm: beats per minute. h.: hour of surgery
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stress. Our results may indicate a slight decrease in the
protective action of sevoflurane during this phase of late
protection.
The main factors that could explain our dissonant re-
sults compared to current literature are the administra-
tion of sevoflurane and the examined population.
Isofluorano studies have shown a dose-dependent pro-
tective effect of anesthetic preconditioning, reveling that
higher concentrations of volatile anesthetic are more pro-
tective than lower concentrations [24–26]. On the other
hand, many studies show benefits of preconditioning only
after prolonged pre ischemic administration of sevoflurane
[27, 28]. It is possible that a protective effect would have
occurred if we had planned higher concentrations or a
longer administration of sevoflurane in our study.
Further considerations regard the female population
under examination. Many studies on animals and on
humans have reported that female hearts have higher tol-
erance for ischemic injury compared to males’ [29, 30].
This difference seems to be determined by the effects of
female hormones. Estrogen contributes to a natural cardi-
oprotection in adult women by reducing oxidative stress,
acting on inflammation factors and improving coronary
flow [31, 32].
In his study on rabbits, Wang [33] speculates that iso-
flurane’s late phase protection is only active for males, not
for females. This gender specificity would be due to the
high baseline levels of endothelial nitric oxide synthase
(eNOS) expressed in females, due to estrogen, which
naturally give additional protection against myocardial
Table 2 Main results. (Results, pag 8, line 173)
BAL Group (n = 27) TCI Group (n = 27) P value
rSO2 (%)
end of surgery 81.8 (8.41) 76.77 (11.42) 0.13
4 h after surgery 84.00 (8.96) 76.16 (12.91) 0.03*
12 h after surgery 84.85 (10.04) 80.33 (14.42) 0.27
20 h after surgery 85.40 (9.97) 80.61 (18.66) 0.32
mean 81.75 (11.07) 78.72 (12.89) 0.37
Clearance Lac
end of surgery/4 h after surgery −98.18 (89.12) −83.85 (107.61) 0.60
end of surgery/20 h after surgery −35.79 (97.64) −37.26 (52.59) 0.95
CPK (iu/l)
preoperative 68.69 (53.99) 56.37 (31.09) 0.31
end of surgery 133.61 (74.07) 184.10 (100.26) 0.04*
4 h after surgery 293.81 (238.66) 294.23 (160.7) 0.99
20 h after surgery 495.19 (530.22) 427.60 (305.19) 0.58
LDH (iu/l)
preoperative 160.11 (93.96) 177.48 (120.56) 0.56
end of surgery 174.70 (120.27) 171.88 (76.49) 0.92
4 h after surgery 389.07 (1182) 188.11 (101) 0.39
20 h after surgery 174.44 (78.67) 184.28 (94.6) 0.68
AST (iu/l)
preoperative 15.77 (6.76) 22.85 (22.72) 0.12
end of surgery 15.40 (5.79) 37.50 (74.74) 0.13
4 h after surgery 16.22 (6.81) 32.10 (48.63) 0.10
20 h after surgery 19.85 (11.74) 28.65 (31.89) 0.19
ALT (iu/l)
preoperative 16.85 (15.5) 20.03 (19.71) 0.51
end of surgery 13.56 (7.68) 38.69 (93.04) 0.17
4 h after surgery 14.60 (9.62) 32.60 (60.81) 0.13
20 h after surgery 15.80 (9.73) 27.30 (51.18) 0.25
All data presented as mean (standard deviation). *Significant. rSO2: regional tissue oximetry; Lac blood lactate, CPK creatine phosphokinase, LDH lactic
dehydrogenase, AST aspartate aminotransferase, ALT alanine aminotransferase
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infarction, but do not grant the benefit of preconditioning
effects of volatile anesthetics in females, through a mech-
anism that has not yet completely been understood.
Another animal study [34] indicated that anesthetic
postconditioning could also lead to gender differences in
cardioprotection. In this case, the protective effect on
males is expressed through the key role of the
phosphatidylinositol-3-kinase (PI3K / Akt) pathway. Due
to estrogen influence, in female rats the PI3K/Akt path-
way was already markedly overexpressed and was not ac-
tivated any further by postconditioning with sevoflurane.
Sevoflurane preconditioning has been widely investigated
in the context of cardiac surgery and clinical studies have
shown that sevoflurane is cardio-protective in cardiac
surgery patients [35], but this effect is ambiguous on other
tissues and organs in different surgical fields [6]. Some
studies on patients undergoing liver resection [36, 37] did
not show significant differences in hepatocyte and endothe-
lial dysfunction markers, nor in postoperative outcomes
between the groups. In addition, results on kidney function
are controversial, and they were unable to report definitive
improvements in the degree of kidney injury [38, 39].
About microvascular breast flap surgery, there are no
studies that have investigated the protective effect of
sevoflurane on ischemia reperfusion injury, also due to
the lack of highly specific blood markers. In our case, we
considered regional O2 inflow measured by NIRS tech-
nology and common markers of cellular damage valid
indicators to assess the damage from IR. Although we
excluded patients with vascular or bleeding pathologies
from the study, the relation between tissue perfusion
and management is complex and multifactorial, so we
tried to minimize counfunding factors by using strict
protocols. Mean arterial pressure was maintained in
established limits using opioids and hypnotic drugs, fluid
therapy was also used to regulated ABP and to replace
loss, the temperature was also maintained constant in
the operating room.
Regarding the weaknesses of our study, this is a multi-
centric trial, so the surgery was conducted by two different
Fig. 3 Postoperative data. All data presented as mean (standard deviation). * Significant. rSO2: regional tissue oximetry. MAP: mean arterial
pressure. SpO2: saturation of peripheral oxygen. HR: heart rate. Bpm: beats per minute. T0: end of surgery, T1 4 h after surgery, T2: 12 h after
surgery, T3: 20 h after surgery
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equipes, this obviously determined a margin of procedure
variability. To minimize this inter-instituitonal gap we
standardized the anesthesiological management while the
surgical procedure was discussed and decided out of
accorded with the two operative teams. Other limits: the
number of patients was relatively small and we used a sin-
gle preconditioning protocol; our study may represent a
starting point for future studies, which will also consider
different volatile anesthetic concentrations and different
preconditioning timings.
Conclusions
In conclusion, the results regarding the rSO2 values
recorded indicate an initial protective effect of sevoflurane
in the treated group, which does not persist in the long-
term. We believe that a prospective, randomized, placebo-
controlled trial that clarifies the effects of volatile anes-
thetics preconditioning with a larger number of patients
could lead in the future to the creation of an anesthesia
plan not only based on the type of surgery, but even
“patient tailored”.
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